poisar

Stocks · News reference

Tilray Brands’ Unit Tilray Medical Secures Key Regulatory Approval For In-House Testing At Portugal Facility

Benzinga Newsdesk

Tilray Medical, a global leader in medical cannabis research, cultivation, production, products and distribution and a division of Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY), today announced a key

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TLRYTSX:TLRY
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  2. David Jagielski, Cpa

    Down 70% in 2026, Has Tilray's Stock Finally Bottomed Out?

    Tilray Brands stock has plummeted 70% in 2026 and 97% over five years despite generating nearly $1 billion in revenue. While the company has grown through acquisitions in beverages and alcohol, it remains unprofitable with an operating loss of $60.5 million over the trailing 12 months. The analyst argues the stock could fall further due to weak organic growth, continued cash burn, and limited profitability prospects, despite its low valuation of $400 million market cap.

    TLRYCGC
  5. Benzinga Insights

    Full Transcript: Tilray Brands Q1 2027 Earnings Call

    Tilray Brands (TSX:TLRY) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga

    TSX:TLRY